Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C119620> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- NCIT_C119620 IAO_0000115 "A bispecific monoclonal antibody directed against both the Notch ligand delta-like 4 (DLL4) and the human tyrosine kinase vascular endothelial growth factor (VEGF), with potential anti-angiogenic and antineoplastic activities. The anti-DLL4 moiety of navicixizumab specifically binds to DLL4, prevents its interaction with Notch receptors, and inhibits Notch-mediated signaling and gene transcription, which may both block tumor angiogenesis and inhibit tumor cell growth. The anti-VEGF moiety binds to VEGF and prevents the binding of VEGF to its receptor, which blocks VEGF-mediated signaling and further inhibits the growth and maintenance of tumor blood vessels. The expression of DLL4 is highly restricted to the vascular endothelium; DLL4/Notch signaling is required for the development of functional tumor blood vessels. The expression of the pro-angiogenic growth factor VEGF is associated with tumor angiogenesis and tumor cell proliferation and invasion." @default.
- NCIT_C119620 NCIT_A32 NCIT_C1909 @default.
- NCIT_C119620 NCIT_NHC0 "C119620" @default.
- NCIT_C119620 NCIT_P106 "Amino Acid, Peptide, or Protein" @default.
- NCIT_C119620 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C119620 NCIT_P107 "Navicixizumab" @default.
- NCIT_C119620 NCIT_P108 "Navicixizumab" @default.
- NCIT_C119620 NCIT_P207 "C3896797" @default.
- NCIT_C119620 NCIT_P210 "1638338-43-8" @default.
- NCIT_C119620 NCIT_P319 "1W14T9L25W" @default.
- NCIT_C119620 NCIT_P322 "CTRP" @default.
- NCIT_C119620 NCIT_P322 "FDA" @default.
- NCIT_C119620 NCIT_P322 "GDC" @default.
- NCIT_C119620 NCIT_P329 "766887" @default.
- NCIT_C119620 NCIT_P330 "766887" @default.
- NCIT_C119620 NCIT_P375 "Anti-DLL4/VEGF Bispecific Monoclonal Antibody OMP-305B83" @default.
- NCIT_C119620 NCIT_P375 "Navicixizumab" @default.
- NCIT_C119620 NCIT_P399 "766887" @default.
- NCIT_C119620 NCIT_R124 NCIT_C17710 @default.
- NCIT_C119620 NCIT_R124 NCIT_C17828 @default.
- NCIT_C119620 NCIT_R124 NCIT_C18219 @default.
- NCIT_C119620 NCIT_R124 NCIT_C19986 @default.
- NCIT_C119620 NCIT_R124 NCIT_C40474 @default.
- NCIT_C119620 normalizedInformationContent "100" @default.
- NCIT_C119620 referenceCount "1" @default.
- NCIT_C119620 hasExactSynonym "Immunoglobulin G2-kappa, Anti-(Homo sapiens DLL4(delta-like 4)) and Anti-(Homo sapiens VEGFA (Vascular Endothelial Growth Factor A,VEGF-a, VEGF)), Humanized and Chimeric Monoclonal Antibody, Bispecific" @default.
- NCIT_C119620 hasExactSynonym "NAVICIXIZUMAB" @default.
- NCIT_C119620 hasExactSynonym "Navicixizumab" @default.
- NCIT_C119620 hasExactSynonym "OMP 305B83" @default.
- NCIT_C119620 hasExactSynonym "OMP-305B83" @default.
- NCIT_C119620 hasExactSynonym "OMP305B83" @default.
- NCIT_C119620 inSubset NCIT_C116977 @default.
- NCIT_C119620 inSubset NCIT_C116978 @default.
- NCIT_C119620 inSubset NCIT_C128784 @default.
- NCIT_C119620 inSubset NCIT_C157711 @default.
- NCIT_C119620 inSubset NCIT_C157712 @default.
- NCIT_C119620 inSubset NCIT_C176424 @default.
- NCIT_C119620 inSubset NCIT_C177537 @default.
- NCIT_C119620 inSubset NCIT_C63923 @default.
- NCIT_C119620 type Class @default.
- NCIT_C119620 isDefinedBy ncit.owl @default.
- NCIT_C119620 label "Navicixizumab" @default.
- NCIT_C119620 subClassOf NCIT_C119620 @default.
- NCIT_C119620 subClassOf NCIT_C129821 @default.
- NCIT_C119620 subClassOf NCIT_C129822 @default.
- NCIT_C119620 subClassOf NCIT_C1454 @default.
- NCIT_C119620 subClassOf NCIT_C163758 @default.
- NCIT_C119620 subClassOf NCIT_C1742 @default.
- NCIT_C119620 subClassOf NCIT_C1908 @default.
- NCIT_C119620 subClassOf NCIT_C1909 @default.
- NCIT_C119620 subClassOf NCIT_C198860 @default.
- NCIT_C119620 subClassOf NCIT_C20401 @default.
- NCIT_C119620 subClassOf NCIT_C2496 @default.
- NCIT_C119620 subClassOf NCIT_C274 @default.
- NCIT_C119620 subClassOf NCIT_C28227 @default.
- NCIT_C119620 subClassOf NCIT_C307 @default.
- NCIT_C119620 subClassOf NCIT_C308 @default.